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Abstract: Aberrant expression and activation of receptor tyrosine kinases (RTK) is a fre-
quent feature of tumor cells that may underlie tumor aggressiveness. Among RTK, Axl, a 
member of the Tyro3-Axl-Mer family, represents a potential therapeutic target in different 
tumor types given its over-expression which leads to activation of oncogenic signaling pro-
moting cell proliferation and survival, as well as migration and invasion. Axl can promote aggressiveness of 
various cell types through PI3K/Akt and/or MAPK/ERK, and its expression can be transcriptionally regulated 
by multiple factors. Deregulated Axl expression and activation have been shown to be implicated in reduced 
sensitivity of tumor cells to target-specific and conventional antitumor agents, but the precise mechanism un-
derlying these phenomena are still poorly understood. Several small molecules acting as Axl inhibitors have 
been reported, and some of them are undergoing clinical investigation. In this review, we describe Axl bio-
logical functions, its expression in cancer and in drug-resistant tumor cells and the development of inhibitors 
tailored to this receptor tyrosine kinase.  
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1. INTRODUCTION 
Cancer cells are characterized by a wide array of al-
terations which favour their survival and are ultimately 
implicated in tumor growth and progression [1]. 
Among them, the activation of RTK is frequent. Al-
though the use of multiple molecular and biochemical 
approaches has led to the identification of alterations 
representing actionable targets for therapeutic interven-
tion, the evidence of tumor heterogeneity, driven in 
part by clonal selection and cell plasticity, suggests that 
greater success could be achieved in the cure of cancer 
by striking crucial hubs. In this perspective, even the 
targeting of a single alteration may impact on multiple 
factors cooperating to maintain cell survival. Among 
the survival pathways involved in sustaining aggressive 
feature of tumor cells such as drug resistance and me-
tastatic behaviour are PI3K/Akt/ mTOR and 
Raf/MEK/ERK, which regulate a variety of cellular 
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processes including growth and metabolism [2, 3]. 
They are aberrantly activated in human tumors mainly 
due to inappropriate activation of RTK or mutations of 
pathway components. 
RTK and other enzymes belonging to survival 
pathways represent important therapeutic targets given 
their role in trasducing physiological signals related to 
growth, adhesion, differentiation, motility and survival, 
from the extracellular environment to the nucleus [4]. 
Fifty-eight RTK have been identified in the human ge-
nome, grouped in 20 subfamilies based on the sequence 
homology [5, 6].  
Several drugs developed to inhibit cell survival fac-
tors are tyrosine kinase (TK) inhibitors which interfere 
with the reaction catalysing the transfer of phosphate 
from high energy donor molecules (i.e., ATP) to sub-
strates at tyrosine residues. The sensitivity of selected 
tumor types to specific TK inhibitors may reflect their 
dependence on a peculiar factor or pathway for sur-
vival, a relationship defined as “oncogene addiction” 
[7]. The available evidence suggests that the inhibition 
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of a single RTK may not be sufficient to inhibit tumor 
growth in a persistent manner due to the cross-talk 
among different members of the RTK family (also re-
ferred to as RTK co-activation), a process which allows 
tumor cells to simultaneously activate two or more 
RTK due to the numerous transduced intracellular sig-
nals [8]. However, it appears that targeting of RTK 
crucial in sustaining multiple aspects of tumor cell ag-
gressiveness may represent a promising strategy. In this 
context, Axl, a member of the Tyro3-Axl-Mer (TAM) 
family of RTK may constitute a valuable candidate to 
inhibit. 
Here, we review the recent literature regarding Axl 
biological functions and the development of strategies 
to inhibit its function by pharmacological tools. 
2. PHYSIOLOGICAL ROLE OF AXL AND TAM 
RECEPTORS 
Originally isolated as transforming gene from pri-
mary human myeloid leukemia cells, Axl was cloned in 
the early nineties and identified as the prototype of a 
novel class of RTK by virtue of its kinase domain 
amino acid sequence and the juxtaposition of fi-
bronectin type III and immunoglobulin-like repeats in 
the extracellular domain (Fig. 1) [9, 10]. The trans-
forming capacity of the gene product, designated as 
Axl from “anexelekto”, a greek word for “uncon-
trolled”, was due to over-expression [9]. The human 
Axl gene is located on chromosome 19q13.2 and in-
cludes 20 exons. The gene is conserved among differ-
ent organisms (e.g., mouse, rat, and non-human pri-
mates), and its role is not essential as supported by the 
observation that knockout mice are viable, without ma-
jor development defects [11]. However, several patho-
logical phenotypes can become evident in adult knock-
out mice, such as autoimmune diseases due to abnor-
mal cytokine release, and accumulation of apoptotic 
cells and tissue necrosis [12]. Thus, Axl does not ap-
pear to be a key factor for embryogenesis, but it exerts 
extremely important functions in differentiated cells.  
Axl appears to be a pleiotropic factor implicated in 
the regulation of multiple processes, even not related to 
cancer. Indeed, Axl signaling is involved in the regula-
tion of the inflammatory response and has been re-
cently linked to acute coronary syndrome [13]. Moreo-
ver, a role in immune activation of smooth muscle cells 
(SMC) in vein graft remodelling has been reported 
[14]. Such functions are consistent with the receptor 
expression in mammalian vascular and immune cells. 
Axl expression is ubiquitous, with expression in plate- 
 
lets, endothelial and renal cells, hepatocytes and 
macrophages, as well as in SMC, cardiac myocytes, 
testis and retina [4] as reported in the literature. 
Besides Axl, two other genes, Tyro-3 and Mer, be-
long to the TAM RTK subfamily. They have unique 
expression profiles, with partial overlap (Table 1 [15]). 
Specifically, Tyro-3 is abundantly expressed in the 
nervous system, as well as in liver, skeletal muscle, 
osteoclasts, and retina [16-21]. Mer is expressed in 
monocytes/macrophages, dendritic cells, natural killer 
(NK) cells, megakaryocytes and platelets [16, 22]. 
High levels of Mer are also found in the testis, lung, 
retina, whereas lower expression is detected in brain, 
heart and skeletal muscle [21, 23]. The biological func-
tions of TAM receptors are extremely diversified and 
depend on cell type and microenvironment; these re-
ceptors can play overlapping or cooperating roles [4], 
whose discussion is beyond the goal of the present re-
view.  
Among TAM receptors, Axl has emerged as a 
promising therapeutic target. In particular, it has been 
reported that Axl is over-expressed in many human 
tumors, including lung, colon, prostate and renal cancer 
[4, 24] and its oncogenic signaling promotes a variety 
of processes such as cell survival and proliferation as 
well as migration and invasion [25]. 
Many aspects of Axl signalling have been clarified 
early after its discovery, and a large body of data has 
been reported in the literature over the years contribut-
ing to build a complex view of the pathways acting 
downstream of Axl (see below). 
2.1. Axl Signaling and Expression Regulation 
Axl activation triggers a number of downstream 
events such as survival, proliferation, migration, adhe-
sion and cytokine production, depending on the cell 
type and the microenvironment. Indeed, Axl has been 
implicated in the survival and migration of neurons in 
the central nervous system (CNS) [26], in the migration 
of SMC after vascular damage [27], in the differentia-
tion and maturation of NK cells [28], and in the clear-
ance of apoptotic cells, a process where macrophages 
and dendritic cells play an essential role [29, 30]. 
The physiological ligand of Axl is Gas6 which 
binds the extracellular domain of the RTK, a phenome-
non resulting in the receptor dimerization and subse-
quent trans-autophosphorylation of tyrosine residues in 
the cytoplasmic kinase domain. Thus, the enzyme 
phosphorylates multiple cellular substrates, forming 
various signaling complexes [31, 32]. Three putative
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Fig. (1). Schematic representation of TAM receptor molecular structure. The different domains of the TAM Receptor Ty-
rosine Kinase (Axl, Mer, Tyro-3) are shown. The receptors are organized as follows: extracellular part with two imunoglobulin-
like and two fibronectin-like domains, transmembrane and intracellular/kinase domains. Three putative autophosphorylation 
sites and conserved motifs, that characterize TAM receptor are indicated inside the kinase domain. 
 
Table 1. Expression of Axl, Tyro-3, Mer and of the Axl ligand Gas6 in normal tissues1. 
Cell type Axl Tyro-3 Mer Gas6 
Endothelial cells +/- +/- +/- +/- 
Monocytes +/- +/- +/- +/- 
Denditic cells +/- +/- +/- ++ 
Natural killers +/- +/- +/- +/- 
Whole blood +/- +/- +/- +/- 
Skeletal muscle +/- + ++ +/- 
Smooth muscle cells +++ +/- + +/- 
Cardiac myocytes +++ + ++ +/- 
Adipocytes + +/- +/- ++ 
Placenta ++ +/- +/- +/- 
Testis/Germ cells ++ +/- ++ + 
Liver +/- + ++ +/- 
Kidney +/- +/- +/- +/- 
Lung + +/- + +++ 
Brain +/- ++ +  +/- 
Heart +/- +/- ++ ++ 
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(Table 1) contd…. 
Cell type Axl Tyro-3 Mer Gas6 
Retina ++ +/- ++ +/- 
Ovary +/- +/- +/- +/- 
Prostate +/- +/- +/- + 
1The profile of expression in normal tissues/cells has been reported according to www.biogps.org [15]; +++ = high abundant expression; ++ = abundant expres-
sion; + = moderate expression; +/- = low expression.  
auto-phosphorylation sites have been reported at the C-
terminus of Axl, i.e, Y-779, Y-821, Y-866. The Y-821 
residue has been shown to interact with phospholipase 
C, inositol-3-phosphate kinase and Grb2 [31, 33]. Un-
der physiological conditions, Axl activation is shut 
down through a variety of mechanisms including re-
ceptor endocytosis and ubiquitination, as well as 
dephosphorylation by tyrosine phosphatases, such as 
the C1-domain containing phosphatase and TENsin 
homologue (C1-TEN). In fact, C1-TEN1, which has 
been described as a negative regulator of the Akt signal 
transduction pathway inhibiting cell survival, prolifera-
tion, and migration [34, 35], has been reported to inter-
act with Axl.  
The extracellular portion of Axl can be cleaved off 
from the membrane to generate soluble Axl (sAxl) [36, 
37]. The soluble fraction of Axl (65KDa) has been de-
tected in human plasma and sera, as well as in condi-
tioned media from cancer cells [36, 38]. Morever, the 
levels of sAxl were correlated to poor prognosis in pa-
tients within renal cancer [39]. More recently, sAxl has 
been suggested as a possible circulating biomarker for 
Neurofibromatosis Type 1 related tumor burden [40]. 
The enzymes involved in the proteolytic cleavage of 
TAM receptors are still unknown. Cleaved Axl was 
proposed to bind Gas6 and to prevent receptor activa-
tion [37].  
Once activated, Axl can promote growth and sur-
vival of various cell types, through different pathways 
including MAPK/ERK e PI3K/Akt. The activation of 
specific pathways is determined by both extracellular 
environment and cell tissue type in a context-dependent 
manner [25] (Fig. 2). 
The relationship between Axl activation and MAPK 
pathway has been evidenced in different studies. Axl 
promotes cell proliferation via activation of Grb2 by 
direct binding with the Y-821 Axl residue [33]. 
Ligand-dependent Axl activation has been shown to 
stimulate MAPK, besides Akt and FAK pathways in 
Non Small Cell Lung Cancer (NSCLC) cell lines [41]. 
In these models, some Axl-dependent effects (i.e., 
clonogenic and tumorigenic abilities) were also ob-
served upon Mer activation, suggesting a partially 
overlapping role for the two RTK in this cell context. A 
relevant role has been ascribed to the Axl/MAPK 
pathway in human gallbladder cancer cell lines, in 
which the transcriptional co-activator Yes-associated 
protein 1 (YAP1) and Axl were over-expressed [42]. In 
this study, a significant correlation was found between 
high expression of YAP1/Axl and poor prognosis, in 
keeping with the described transcriptional regulation of 
Axl expression by YAP1 [43]. Thus, in selected tumor 
types a direct link between Axl and Akt/ERK down-
stream pathways is clearly documented. In fact, YAP1 
silencing switches off Axl activation and results in Akt 
and ERK dephosphorylation [42]. Of note, Axl was 
shown to be a relevant downstream target in YAP1-
dependent oncogenic functions also in hepatocellular 
carcinoma cell lines [44].  
Besides, Axl has been described as direct transcrip-
tional target of the Hippo pathway effector transcrip-
tional co-activator with PDZ-binding motif (TAZ), 
which has been reported to contribute to gefitinib resis-
tance of NSCLC cells harbouring epidermal growth 
factor receptor (EGFR)-T790M mutation [45]. 
Additional transcription factors have been impli-
cated in regulating Axl expression in solid tumors (Fig. 
3). The Sp1/Sp3 transcription factors have been linked 
to Axl constitutive expression; these proteins have been 
shown to bind GC-rich regions in the Axl promoter to 
upregulate its transcription, whereas methylation of 
CpG sites in Sp binding regions restricts Axl gene ex-
pression [46]. Over-expression of Myeloid Zinc Fin-
ger-1 (MZF-1) has been shown to result in Axl transac-
tivation and to promote invasion in solid tumors, using 
in vitro and in vivo models [46, 47]. In addition, epige-
netic regulation of Axl expression is supported by other 
studies. For example, transcriptional control of Axl has 
been proposed to occur in glioma cells through enhan-
cer of zeste homolog 2 (EZH2), that is overexpressed 
in a variety of human cancers including glioma [48]. 
Such a factor controls epigenetic silencing of gene
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Fig. (2). Pathways downstream of Axl receptor. Schematic representation of cellular pathways activated down-stream of Axl 
receptor. Axl is implicated in regulating cell proliferation, migration, mainly through the activation of the canonical MAPK 
pathway (ERK1/2) and in cell survival via PI3K-Akt. Arrows stand for activating signals; ┴ stand for inhibitory signals. 
 
Fig. (3). Transcription factors involved in regulation of Axl expression in tumors. The arrows refer to 19 CpG methylation 
sites within nucleotides -669 and -97. 
transcription through histone H3 lysine trimethylation 
acting as a silencer of tumor suppressor genes, thereby 
driving glioma malignancy via Axl transcription con-
trol. 
Regulation of Axl levels has been also related to 
gain of function activities of mutant p53 in lung cancer 
cell lines [49]. In fact, mutant p53 enhanced the forma-
tion of acetylated histones on the Axl promoter. Of 
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note, mutant p53 up-regulated the Axl promoter inde-
pendently of p53/p63 binding sites. 
The available evidence supports that Axl activation, 
besides stimulating the MAPK/ERK pathways, results 
in PI3K/Akt stimulation, thereby leading to the expres-
sion of anti-apoptotic proteins. In this regard, NF-kB 
activation and nuclear translocation have been docu-
mented to increase the expression of anti-apoptotic pro-
teins such as Bcl-2 e Bcl-XL and to inhibit pro-
apoptotic factors such as caspase 3 [50, 51]. Moreover, 
Gas6 triggers the phosphorylation of the pro-apoptotic 
protein Bad, a well known target of Akt, that maintains 
a survival signal when phosphorylated [52].  
3. AXL AND CANCER 
3.1. Axl and Gas6 Expression in Tumors 
Although originally identified in chronic myeloge-
neous leukemia [9], the available literature supports 
that Axl is expressed in a variety of tumor types (Table 
2). Gas6, the only activating Axl ligand has also been 
reported to be expressed in tumors and, in principle, 
may also be present in the tumor microenvironment 
(e.g. stroma cells).  
3.2. Regulation of Cell Aggressiveness 
Axl has been shown to contribute to the metastatic 
process, angiogenesis and cell survival in different ex-
perimental models through multiple pathways. A link 
between Axl expression and oxidative stress has been 
recently reported [53]. Using lung adenocarcinoma cell 
lines exhibiting different metastatic potential, it has 
been demonstrated that Axl activation elicits reactive 
oxygen species (ROS) accumulation through the oxi-
dase-coupled small GTPase Rac1. Of note, Axl was 
activated by oxidative stress, leading to enhanced cell 
migration via the PI3K/Akt pathway. Akt1 targeting 
impaired hydrogen-peroxide induced migration and 
inhibited Rac1 activation, suggesting redox regulation 
in Axl-related malignant cell migration [53]. In addi-
tion, ROS-mediated Gas6 secretion has been reported 
as an early event of arginine auxotrophic response in 
cancer cells, where the auxotrophic challenge provides 
PI3K/Akt pathway activation and c-Myc protein stabi-
lization as well as myc transcriptional induction, fur-
ther supporting feedback mechanisms to enhance Axl 
expression [54].  
Aberrant expression of Axl can lead to increased 
migration, thereby favouring invasion of tissues sur-
rounding tumor cells [55]. The Axl kinase domain can 
mediate  the  binding  with  actin cytoskeleton, whereas 
Table 2. Axl expression in different tumor types1. 
Tumor type References 
Lung [41, 45, 49, 82, 83, 84, 88, 90, 
91] 
Breast  [55, 80, 103] 
Colon [47, 57] 
Liver [44] 
Pancreas [60] 
Kidney [39] 
Melanoma [77-79] 
Cutaneous squamous cell can-
cer 
[56] 
Glioblastoma  [48, 63, 66] 
Ovarian  [68, 69] 
Prostate [70] 
Esophageal squamous cell [87] 
Head and neck  [81, 87] 
Mesothelioma [72-74] 
Osteosarcoma  [75, 76] 
Gastrintestinal stromal (GIST) [8] 
Myeloid leukemia [9] 
Acute myeloid leukemia [89] 
Chronic myeloid leukemia [97] 
Chronic lymphocytic leukemia 
B cells 
[101] 
1 The tumor subtypes mentioned in the review are reported. Gas6 is men-
tioned in Ref. [39, 63, 77]. 
the extracellular domain contains motifs which are im-
portant in the adhesion between cells [4, 26]. Thus, the 
structural features of the receptor support its role in the 
establishment of cell-cell contacts. In this regard, it has 
been shown that Axl knockdown results in increased 
cell-cell attachment of cutaneous squamous cell carci-
noma cells; this behaviour was associated with de-
creased expression of desmoplakin I in the cytoskeletal 
fraction, whereas desmoplakin II, plakoglobin, desmo-
somal cadherin and plakophilin expression levels re-
mained unchanged. Moreover, cellular studies evi-
denced changes of the levels of components of tight 
junctions upon Axl knockdown (i.e., up-regulation of 
proteins of the zonula occludens and decrease of 
claudins) as well as up-regulation of E-cadherin - a 
component of adherent junctions - and increase mem-
brane localization of plakoglobin, p120-catenin and 
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alfa-catenin [56]. In addition, Axl depletion resulted in 
downregulation of Wnt and TGFbetaR signaling [56]. 
Axl has been shown to be constitutively phosphory-
lated in a human tumor subline derived from the colon 
carcinoma HCT116 cell line, exhibiting enhanced inva-
sive ability [57]. This observation has led to the hy-
pothesis that Axl may be implicated in epithelial to 
mesenchymal transition (EMT) [57], a finely regulated 
process, frequently occurring during tumor progres-
sion, that results in the acquisition of a pro-invasive 
phenotype coupled to strongly enhanced survival capa-
bilities [58]. This process involves molecular, bio-
chemical and cellular changes leading to an alteration 
of cell-cell and cell-matrix interactions, actin cy-
toskeletal reorganization, and activation of new tran-
scriptional programs to maintain a mesenchymal phe-
notype [59]. In this context, Axl has been reported to 
control expression of Snail, Slug and Twist mRNA ex-
pression, which act as transcriptional repressors and 
play a key role in the phenotypic switch towards EMT 
[60]. 
Moreover, it has been shown that the migratory ca-
pability of Gas6 expressing vascular SMC was corre-
lated with Axl kinase activity [61]. Thus, this receptor 
is likely to participate also in neo-angiogenesis which 
promotes tumor proliferation as Gas6/Axl downstream 
signaling favours cell survival. 
Overall, it seems that increased Axl expression cor-
relates with enhanced tumor cell invasive abilities, that 
are features associated with reduced patient survival 
[57]. Thus, by virtue of its contribution to tumor ag-
gressiveness Axl represents a promising therapeutic 
target. Its pleiotropic biological role should be taken 
into account as a possible source of side effects in anti-
tumor treatment based on Axl inhibition. 
3.3. Regulation of Cell Survival 
Axl expression has been shown to be altered in dif-
ferent tumor types, the oncogenic potential of the re-
ceptor being related to an aberrant regulation of cell 
survival. The TAM family of RTK is markedly ex-
pressed during the development of the CNS and de-
regulated activation of these RTK has been shown in 
different CNS-related disorders including brain tumors 
[62]. Several members of the RTK family have been 
proposed as promising therapeutic targets in glioblas-
toma multiforme (GBM), an aggressive form of brain 
tumor in which surgery, radiotherapy and temo-
zolomide-based treatment fail to improve patient sur-
vival. Axl and its ligand Gas6 are frequently aberrantly 
expressed in human glioma and in vascular cells of 
neoplastic brain tissue, likely contributing to the poor 
clinical outcome of GBM patients [63]. The receptor 
and its ligand, frequently overexpressed in tumors, are 
likely to generate autocrine and paracrine stimulation 
loops. Moreover, given their pattern of co-expression, 
they appear to be involved in neo-vascularization of 
GBM. The role of Axl in maintaining the disease ag-
gressiveness is also supported by its expression in 
stem-like GBM cells, particularly in those of the mes-
enchymal subtype, in which the receptor is expressed 
and phosphorylated, as evidenced by transcriptomic 
expression and kinome-wide short hairpin RNA screen-
ing [64]. The malignant phenotype of GBM appears to 
involve multiple members of the TAM family. In fact, 
in adult and paediatric glioblastoma cell lines, 
foretinib/XL880 (see paragraph 4.1), a RTK inhibitor 
currently undergoing clinical investigation, markedly 
inhibited Mer. The natural compound n-butylidene-
phtalide derived from Angelica sinensis has been found 
to display antitumor effects in vitro and in vivo, which 
are mediated by different mechanisms, including re-
duction of Axl expression in brain tumors [65]. Spe-
cifically, treatment with n-butylidenephtalide has been 
shown to result in decreased Axl expression, down-
regulation of matrix metalloproteinase activity and de-
creased expression of genes involved in EMT transition 
in GBM experimental models [65]. Of note, controlled-
release of the agent by a polymer wafer increased local 
drug concentration being active in situ in an intracra-
nial tumor model of glioblastoma [66]. 
Axl has been shown to exhibit deregulated expres-
sion in ovarian carcinoma cells with acquired resis-
tance to cisplatin [67], although a clear and univocal 
role for the kinase was not established. Of note, a 
marked fraction of Axl expressing tumors was identi-
fied among ovarian adenocarcinomas, particularly in 
G3 and stage III-IV tumors, Axl expression being a 
negative prognostic marker [68]. In a recent study, Axl 
signaling has been reported to converge on the integrin 
β3 pathway and to induce tumor cell adhesion to the 
extracellular matrix and invasion in high grade epithe-
lial ovarian cancer [69]. 
Gas6 has been reported to induce proliferation of 
prostate cancer cells expressing Axl [70]. In this con-
text, the mitogenic effect was proportional to Axl ex-
pression and related to Akt and MAPK phosphoryla-
tion.  
Exposure of tumor cells to apigenin (4',5,7-
trihydroxyflavone), a natural product of the flavonoid 
class, was shown to result in inhibition of the prolifera-
tion and clonogenic ability of NSCLC cell lines in as-
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sociation with a decrease of Axl mRNA and protein 
levels [71]. Since cell-cycle and apoptosis–related ef-
fects of apigenin appeared to be dependent on Axl lev-
els, as they were modulated when Axl levels were in-
creased or decreased using functional approaches, the 
RTK seems to be a relevant target of apigenin [71].  
Co-activation of multiple RTK including Axl has 
been reported in mesothelioma cell lines in which the 
pro-apoptotic and anti-proliferative effects of the si-
multaneous inhibition of different kinases may be 
promising [72]. In fact, in this tumor type activation of 
the PI3K/Akt and Raf/MEK/MAPK pathways was 
shown to be dependent on the coordinated activation of 
EGFR, MET and Axl. Indeed, dual targeting of PI3K 
and mTOR pathways produced marked proliferation 
inhibition, suggesting a greater effect than inhibition of 
single kinases [67]. In keeping with this study, Ou WB 
et al. [73] reported that the combination of inhibitors of 
multiple RTK including Axl in mesothelioma cells to-
gether with targeting of the RTK chaperone HSP90, 
allowed to achieve a substantial inhibition of prolifera-
tion and survival. Over-expression of Axl was reported 
in primary specimens of pleural mesothelioma [74]. 
Over-expression, found in the majority of malignant 
pleural mesothelioma specimens, was shown to influ-
ence patient survival, independently of other estab-
lished prognostic factors [74]. Axl has been proposed 
as a therapeutic target also in osteosarcoma, being 
among the most frequently activated RTK [75]. In 
keeping with this evidence, Gas6/Axl have been re-
ported to inhibit apoptosis and to promote migration 
and invasion of osteosarcoma cells [76]. Increased ex-
pression of activated Axl has been related to recurrence 
and lung metastasis and Gas6/Axl were shown to pre-
dict clinical outcome in association with MMP-9 and 
Akt, but not ERK signaling [76]. Axl has been recently 
reported to be frequently expressed and to regulate cell 
proliferation and migration in melanoma cell lines, 
harbouring NRAS mutations [77, 78], where it has 
been identified as an activated RTK by proteomic ap-
proaches [78]. In a recent study, over-expression of Axl 
has been detected in different melanoma subtypes in-
trinsically resistant to BRAF inhibition [79].  
3.4. Axl and Drug Resistance 
Deregulated Axl expression and activation have 
been implicated in the reduced sensitivity of tumor 
cells to target-specific and conventional antitumor 
agents in different preclinical models. 
Gastrointestinal stromal tumor (GIST) cells display-
ing acquired resistance to imatinib, a well known in-
hibitor of Kit and PDGF receptor which have been im-
plicated in the pathogenesis of GIST, have been found 
to exhibit Axl over-expression by virtue of a kinase 
switch [8]. Indeed, imatinib-resistant cells were charac-
terized by reduced Kit and increased Axl expression. 
Since the Axl ligand was over-expressed in these cells, 
the kinase activation was the consequence of the pres-
ence of an autocrine loop. In breast cancer cells with 
acquired resistance to lapatinib, a potent and selective 
inhibitor of HER1 e HER2 widely used in the treatment 
of metastatic breast cancer, an association between la-
patinib resistance and Axl over-expression was found 
[80]. In these cells, the mechanism leading to the re-
ceptor over-expression was linked to the promoter hy-
pomethylation. Head and neck cancer cells with ac-
quired resistance to the EGFR inhibitor erlotinib were 
characterized by Axl hyper-activation associated to 
enhanced migratory capability [81]. Such an observa-
tion is clinically relevant because high mRNA Axl lev-
els were related to unfavourable prognosis in this tumor 
type [81]. In NSCLC, Axl activation was shown to 
confer resistance to EGFR targeting agents commonly 
employed in the treatment of patients bearing tumors 
with activating EGFR mutations [82]. Axl activation 
seems to be associated to erlotinib resistance in the ab-
sence of secondary EGFR mutations or activation of 
other RTK such as MET [82]. The relevance of Axl in 
such a tumor type is supported by in vitro and in vivo 
experiments showing that genetic and pharmacological 
inhibition of Axl can restore sensitivity to erlotinib 
[82]. In an additional report, evidence has been pro-
vided that Axl can contribute to drug resistance of cells 
treated with EGFR inhibitors, i.e. gefitinib and er-
lotinib. Indeed, using in vitro and in vivo preclinical 
models, combined exposure to erlotinib and to an Axl 
inhibitor could overcome resistance to the EGFR in-
hibitor through a marked impairment of EGFR down-
stream signaling [83]. Moreover, in another NSCLC 
cell line, Axl did not play any role in erlotinib resis-
tance, underlying the complexity of the drug-resistant 
phenotype [84]. Recently, Axl silencing was shown to 
be unable to reverse erlotinib resistance in NSCLC cell 
lines. Since these cells underwent EMT, it appears con-
ceivable that Axl inhibition is not sufficient to over-
come resistance under such a condition [85]. A role for 
Axl in resistance to EGFR inhibitors is also confirmed 
by a study carried out in NSCLC clones and tumor 
xenograft models resistant to the EGFR targeting anti-
body cetuximab, which exhibit increased Axl expres-
sion and activation [86]. The cells appeared to be de-
pendent on Axl for their proliferation through EGFR 
and down-stream signaling activation [86]. In fact, Axl 
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stimulated cell proliferation, EGFR activation and 
MAPK signaling; furthermore, EGFR itself directly 
regulated Axl expression, creating a positive feedback 
loop to maintain the activation of EGFR by Axl. In 
preclinical models and clinical specimens, Axl overex-
pression was associated with resistance to PI3Kα in-
hibitors; of note, Axl expression and its interaction 
with EGFR were found to be associated also with resis-
tance to PI3Kα inhibitors and with persistent 
PI3K/Akt-independent mTOR activation in head and 
neck and esophageal squamous cell carcinomas [87]. 
Indeed, it has been demonstrated that Axl transactivates 
EGFR in a ligand-independent manner and induces its 
phosphorylation on Tyr1173, thus resulting in PLCγ 
and PKC activation that, in turn, leads to a PI3K/Akt-
independent mTOR activation. Therefore, the com-
bined treatment with PI3Kα inhibitors and either 
EGFR, Axl or PKC inhibitors was able to overcome 
acquired and intrinsic resistance to PI3Kα inhibition in 
squamous cell carcinoma cells [87]. 
Little information is currently available regarding 
the role of Axl in resistance to conventional antitumor 
agents. Using a panel of different human tumor cell 
lines, a synergistic interaction between the antimitotic 
agent docetaxel and BGB324/R428 (see paragraph 
4.1), the first-in-class and most specific Axl inhibitor, 
has been reported in cells with a mesenchymal pheno-
type, characterized by Axl expression. A favourable 
antitumor effect of the combination was also observed 
in in vivo models [85]. In this context, no synergistic 
interaction was found between the Axl inhibitor and 
cisplatin. However, a sensitization to docetaxel was 
observed in cells resistant to erlotinib and cross-
resistant to the taxane, upon Axl pharmacological inhi-
bition [85]. Moreover, it has been shown that the green 
tea-derived catechin inhibited cell proliferation in asso-
ciation with down-regulation of Axl and Tyro3 expres-
sion in cisplatin-sensitive and -resistant NSCLC cells 
[88]. However, Axl role in this phenomenon has not 
been clearly defined, because no functional approaches 
were employed in the study. Using clinical samples 
from acute myeloid leukemia (AML) patients, it was 
found that Axl was the only factor over-expressed in 
chemotherapy refractory patients [89].  
Axl overexpression in AML U937 cells resulted in 
the acquisition of a multidrug-resistant phenotype in-
volving doxorubicin, cisplatin and etoposide only when 
cells were pre-treated with the Gas6 ligand [89]. Using 
proteomic approaches, MET, IGF, and Axl signaling 
have been identified as co-drivers of resistance to 
EGFR inhibitors besides mutant EGFR [90]. In a recent 
study, carried out in a cell line with acquired resistance 
to gefitinib, Axl overexpression has been shown to re-
sult from a slow turnover and defective degradation by 
presenilin-dependent intramembrane proteolysis [91]. 
Overall, the mechanisms leading to increased level of 
Axl in drug-resistant cells and tumors appear to be 
multiple. 
4. DEVELOPMENT OF AXL INHIBITORS 
4.1. From Chemistry to Pharmacology 
A number of compounds with different chemical 
structures have been reported in the literature as being 
capable of inhibiting Axl (Table 3, Figs. 4 and 5). Un-
der most circumstances, such compounds were devel-
oped to inhibit other kinases, and then found to be ac-
tive on Axl. A general strategy that has been pursued to 
obtain kinase inhibitors is the synthesis of compounds 
able to bind the ATP binding site of the enzyme. It has 
been documented that this domain may exist in two 
different conformations, named “DGF-in” and “DGF-
out”, related respectively to an active and to an inactive 
form of the enzyme and referring to the orientation 
(with respect to the active site) of a highly conserved 
sequence (Asp-Phe-Gly) placed in close proximity of a 
so called “activation loop” [92]. However just few 
kinases have been shown to exist in the latter confor-
mation such as c-Abl which is stabilized in its “out” 
form by the binding with imatinib [92, 93]. The con-
formational differences of the active site represent the 
basis of kinase inhibitors classification. Specifically 
compounds binding a kinase in its “DGF-in” form are 
named “type I inhibitors”, conversely “type II” inhibi-
tors bind the “DGF-out” form of the enzyme [94]. The 
active “DGF-in” conformation appears to be more con-
served than the inactive “DGF-out” that shows higher 
variability among the kinases, thus type II are generally 
expected to be more selective than type I inhibitors 
even if this seems not to be a general rule [95]. 
Among the most relevant large spectrum inhibitors, 
recently reviewed by Feneyrolles et al. [25], are clini-
cally approved drugs such as bosutinib/SKI-606, cabo-
zantinib and sunitinib, besides foretinib/XL-880 and 
MGCD265, currently undergoing phase II evaluation 
[96]. Bosutinib is a second-generation dual Src/Abl TK 
inhibitor approximately ten times more potent than 
imatinib, which was recently approved by FDA and 
EMA as a second line option for CML treatment [97]. 
Four additional compounds are in phase I, namely 
BMS777607, LY2801653 (Merestinib), S49076 and 
BGB324/R428. In addition, TP0903 and SGI7079 have 
been reported as promising molecules emerging from 
preclinical studies, because their potency towards Axl 
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Table 3. Axl inhibitors in preclinical or clinical development1. 
Compound IUPAC Name  Target(s)  Tumor types Development  
Bosutinib/SKI-606   4-[(2,4-dichloro-5-
methoxyphenyl)amino]- 6-methoxy-
7-[3-(4-methyl-1-piperazinyl) pro-
poxy]- 3-quinolinecarbonitrile, 
Bcr-Abl-1,Src, Axl  Ph+ CML patient (FDA, 
2012), glioblastomas, breast 
cancer 
Phase II 
NCT02130557 
Cabozantinib N'-[4-[(6,7-dimethoxy-4-
quinolinyl)oxy] phenyl]-N-(4-
fluorophenyl)-1,1- cyclopropanedi-
carboxamide 
VEGFR-2, c-Met, 
Ret Kit, Flt-1/3/4, 
Tie, Axl 
medullary thyroid cancer 
(FDA 2012), hepatocellular, 
renal, prostate cancer 
Phase III 
NCT01908426 
Sunitinib   N-[2-(diethylamino)ethyl]-5-[(Z)-(5-
fluoro-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-2,4-dimethyl-1H-
pyrrole-3-carboxamide, 
Flt-3, Kit, Axl 
VEGFR-2 
renal cell carcinomas, 
imatinib-resistant gasto- in-
testinal stromal tumors (FDA, 
2006), pancreatic neuroendo-
crine tumors (FDA, 2011), 
NSCLC, renal carcinomas 
Phase II 
NCT01306045 
NCT00375674 
Foretinib/XL-880  N-[3-fluoro-4-[[6-methoxy-7-[3-(4-
morpholinyl) propoxy]-4-
quinolinyl]oxy]phenyl]-N'-(4- fluoro-
phenyl)-1,1-
cyclopropanedicarboxamide, 
 Met, VEGFR-2, 
Ron Tie-2, Kit, Axl 
NSCLC, breast cancer Phase I/II 
NCT02034097 
NCT01147484 
MGCD265   N-[[[3-fluoro-4-[[2-(1-methyl-1H-
imidazol-4-yl)thieno[3,2-b]pyridin-7-
yl]oxy]phenyl]amino] thioxomethyl]-
benzeneacetamide, 
Met, Ron, Tie-2, 
VEGFR-1/2/3, Axl 
NSCLC, advanced malignan-
cies 
Phase I/II 
NCT02544633 
BMS777607   N-[4-[(2-amino-3-chloro-4-
pyridinyl)oxy]- 3-fluorophenyl]-4-
ethoxy-1-(4-fluorophenyl)-1,2- dihy-
dro-2-oxo-3-pyridinecarboxamide 
Met, Ron, Flt-3, 
Tyro-3, Mer, Axl 
advanced or metastatic solid 
tumors 
Phase I 
NCT00605618 
LY2801653/ Mer-
estinib 
N-[3-fluoro-4-[[1-methyl-6-(1H-
pyrazol-4-yl)-1H- indazol-5-
yl]oxy]phenyl]-1-(4-fluorophenyl)-
1,2- dihydro-6-methyl-2-oxo-3-
pyridinecarboxamide, 
 Ron, Met, Axl, Flt-
3 
advanced cancer Phase I 
NCT01285037 
S49076   3-[[2,3-dihydro-3-[[4-(4-
morpholinylmethyl)- 1H-pyrrol-2-
yl]methylene]-2-oxo-1H-indol-5-yl] 
methyl]-2,4-thiazolidinedione 
Met, FGFR-1/2/3, 
Axl 
 advanced solid tumors Phase I 
CL1-49076-001 
BGB324/R428  1-(6,7-dihydro-5H-
benzo[6,7]cyclohepta[1,2-c]pyridazin-
3-yl)-N3-[(7S)-6,7,8,9-tetrahydro- 7-
(1-pyrrolidinyl)-5H-
benzocyclohepten-2-yl]- 1H-1,2,4-
triazole-3,5-diamine 
Axl, Tie-2, Flt-4, 
Flt-1, Abl, Tyro-3, 
Mer 
 aggressive and metastatic 
cancer 
Phase I 
(2013) 
TP0903  2-[[5-chloro-2-[[4-[(4-methyl-1-
piperazinyl) methyl]phenyl]amino]-4-
pyrimidinyl]amino]-N, N-dimethyl-
benzenesulfonamide, 
Axl, Aurora A, 
Jak2, Alk, Abl, 
Tyro-3, Mer 
 pancreatic can-
cer,glioblastoma 
Preclinical 
SGI7079  3-[2-[[3-fluoro-4-(4-methyl-1-
piperazinyl) phenyl]amino]-5-methyl-
7H-pyrrolo[2,3-d] pyrimidin- 4-yl]-
benzeneacetonitrile 
Axl, Flt-3, Mer, 
Met, TrkA/B, Ret, 
Yes, Jak2, JNK, 
VEGFR-2, Abl 
 NSCLC Preclinical 
Amuvatinib/ MP-
470 
N-(1,3-benzodioxol-5-ylmethyl)-4-
benzofuro[3,2-d]pyrimidin-4-yl-1-
piperazinecarbothioamide 
c-kit, PDGFRα, 
Met, Flt-3, Axl 
/ Suspended stud-
ies 
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(Table 3) contd… 
Compound IUPAC Name  Target(s)  Tumor types Development  
SNS314  N-(3-chlorophenyl)-N'-[5-[2-
(thieno[3,2-d] pyrimidin-4-
ylamino)ethyl]-2-thiazolyl]urea 
pan-Aurora kinase, 
+7 kinase including 
Axl 
/ Suspended stud-
ies 
NPS-1034  2-(4-fluorophenyl)-N-[3-fluoro-4-[(3-
phenyl-1H-pyrrolo[2,3-b]pyridin-4-
yl)oxy]phenyl]-2,3- dihydro-1,5-
dimethyl-3-oxo-1H-Pyrazole-4-
carboxamide 
Met, Axl lung cancer Preclinical 
LDC1267  N-[4-[(6,7-dimethoxy-4-
quinolinyl)oxy]-3- fluorophenyl]-4-
ethoxy-1-(4-fluoro-2-methylphenyl)- 
1H-pyrazole-3-carboxamide 
TAM kinase, Met, 
Aurora B, Lck, Src, 
CDK8 
 melanoma Preclinical 
NA80x1  4-[(2,4-dichlorophenyl)amino]-6, 7-
dimethoxy-3-quinolinecarbonitrile 
Src, more other 
kinase including 
Axl 
/ / 
SP2215/ Gilterit-
inib 
6-ethyl-3-[[3-methoxy-4-[4-(4-methyl-
1- piperazinyl)-1-
piperidinyl]phenyl]amino]-5- [(tetra-
hydro-2H-pyran-4-yl)amino]- 2-
pyrazinecarboxamide 
Flt-2/3, Axl, Alk AML, advanced solid tumors Phase III/I 
NCT02421939 
NCT02456883 
purine derivative 
(1428155-28-5) 
1-(4-fluorophenyl)-N-[3-fluoro-4-(9H-
purin-6-yloxy)phenyl]-1,2-dihydro-2-
oxo- 3-pyridinecarboxamide 
TAM family recep-
tor 
/ / 
Aminopyrimidine 
derivative 
(1520853-22-8) 
N-[4-[(6-amino-4-pyrimidinyl)oxy]-3- 
fluorophenyl]-1-(4-fluorophenyl)-1,2-
dihydro-2-oxo-3-pyridinecarboxamide 
Met, TAM receptor / / 
UNC569  1-[(trans-4-aminocyclohexyl)methyl]-
N-butyl- 3-(4-fluorophenyl)-1H-
pyrazolo [3,4-d]pyrimidin-6-amine 
Mer, Axl acute lymphoblastic leukemia / 
DP3975 /  Axl mesothelioma Preclinical 
MGCD51 / Axl / / 
1 The IUPAC names of the inhibitors are shown when available, besides the known targets, the tumor types where the compounds were studied and the devel-
opment status. Trial reference id from ref 95 (https://clinicaltrials.gov).  
 
appears to be in the nanomolar range in cell-free as-
says. A specific inhibition of Axl activation was also 
observed after exposure to the BGB324/R428 Axl in-
hibitor of two human GBM cell lines which resulted in 
survival and proliferation inhibition, and migration and 
invasion suppression [98]. The available evidence sug-
gests that Tyro3 cooperates with Axl in sustaining ag-
gressive features of tumor cells in these cellular models 
[98]. 
Amuvatinib/MP-470, an orally bioavailable syn-
thetic carbothioamide, has already started the clinical 
evaluation due to its capability to inhibit mutant forms 
of RTKs (e.g. c-Met, Ret, c-Kit) and to suppress the 
induction of the DNA repair protein RAD51 in cell 
lines [99]. Results from a phase I trial suggested that 
the compound is well tolerated [100]. Interestingly, 
Amuvatinib displays the capability to inhibit also Axl, 
its potency towards the target being in the micromolar 
range [25]. The Aurora Kinase pan-inhibitor SNS314, 
for which safety and tolerability studies have been car-
ried out in patients [96], is described as capable of in-
hibiting Axl with an IC50 in the nM range. Although 
further effort is required to rank the selectivity of the 
available inhibitors, TP0903 and BGB324/R428 have 
been recognized as the most specific towards Axl [25], 
TP0903 being also promising for chronic lymphoid 
leukemia treatment due to its effect per se and in com-
bination with BTK inhibitors in in vitro studies [101]. 
The above-mentioned multitargeted compounds [102] 
and also NPS-1034 [83], LDC1267, NA80x1 [103], 
MGCD516, ASP2215 (Gilteritinib), and DP3975 (the 
only one still under investigation at the preclinical 
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Fig. (4). Chemical structures of Axl inhibitors. The mentioned type I inhibitors of Axl with the exclusion DP3975 and 
MGCD516, whose structures are not available, are shown. 
 
Fig. (5). Chemical structures of Axl inhibitors. The mentioned type II inhibitors of Axl are shown. 
 
level) are being evaluated in phaseI/II clinical trials. It 
has to be noted that the majority of the available kinase 
inhibitors are type I (Fig. 4) and, among the above 
mentioned inhibitors of Axl, only BMS777607, 
foretinib, LY2801653 [25, 104] and LDC1267 [105], 
are type II inhibitors (Fig. 5).  
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The synthesis of inhibitors more selective for the 
TAM family has been recently reported. In particular, 
the type II BMS777607 was modified by replacing its 
pyridine with a purine [94] or with an aminopyrimidine 
[106] ring obtaining compounds with enhanced selec-
tivity. In both cases, ring modification increased the 
selectivity towards TAM allowing the synthesis of 
likely type II inhibitors. The most active purine deriva-
tive (CAS Registry Number 1428155-28-5) together 
with one active aminopyrimidine derivative (CAS Reg-
istry Number 1520853-22-8) are shown in Fig. (5). The 
first one resulted to be a potent inhibitor of Axl and 
Mer, but remarkedly less active towards Tyro3. Efforts 
have also been made to study the selectivity of TAM 
inhibitors through computational approaches. Specifi-
cally, on the basis of experimental X-ray data available 
for c-Met kinase, Messoussi et al. [104] were able to 
identify the specific amino acids implicated in the bind-
ing of the inhibitors in both DFG-in and DFG-out con-
formations of Axl, Tyro3 and Mer kinases. The authors 
validated the obtained DFG-in and DFG-out homology 
models of the three TAM kinases by docking them 
with the type I UNC569, the first-in-class Mer-
selective small molecule inhibitor (Fig. 4) [107] and 
type II BMS777607 inhibitors (Fig. 5). They also sub-
mitted to virtual screening 156 known TAM inhibitors 
(from public databases) docking most of them into the 
DFG-in model and only five into the DFG-out, finding 
that a terminal p-fluorophenyl group is crucial for type 
II inhibitors [10, 107]. Very recently, the pyra-
zolopyrimidine TAM inhibitor UNC569 [107] has also 
been used as a reference compound in a virtual screen-
ing study aimed at finding Mer kinase inhibitors [108], 
owing to its high resolution crystal structure in com-
plex with the Mer kinase domain [107]. Of note, 
UNC569 was found to be effective against lymphoblas-
tic leukemia in vitro and in vivo [109].  
CONCLUSION 
From the development of the first TK inhibitors 
which have been introduced into the clinical practice at 
the beginning of this century, many small molecules 
have been tested at the preclinical level, and new gen-
erations of inhibitors have been proposed. RTK repre-
sent amenable targets for therapeutic intervention and 
ATP competitive inhibitors are endowed with the po-
tential to affect the function of multiple receptors of the 
family. In this regard, type II inhibitors have been hy-
pothesized as being more selective. The use of RTK 
inhibitors in combination with conventional antitumor 
agents may also be promising, in view of the role of 
RTK and downstream pathways in sustaining multiple 
survival features of tumor cells, such as, for example, 
repair of drug-induced damage [3]. In addition, the ac-
quired knowledge on the cross talk of different path-
ways driven by RTK supports that the simultaneous 
targeting of multiple RTK may be effective. This strat-
egy appears to be promising also considering the occur-
rence of the activation of compensatory drug-resistance 
mechanisms preventing the action of RTK inhibitors in 
tumor cells. However, given the multiple physiological 
roles played by RTK, the development of selective in-
hibitors may be still pursued to minimize side-effects 
and it seems likely that the ongoing medicinal chemis-
try effort will lead to the optimization of small mole-
cules specifically targeting selected kinases including 
Axl, through a new generation of type II inhibitors 
based on the availability of new protein crystal struc-
tures and related computational studies. Based on its 
biological role and recognized capability to control a 
plethora of cellular functions of tumor cells, Axl repre-
sents a valuable therapeutic target in different tumor 
types. In this regard, it has to be noted that Axl inhibi-
tion results in minimal toxicity although Axl role in 
limiting inflammation would suggest opposing anti-
inflammatory and oncogenic role for this kinase. Posi-
tive results from a phase Ia dose escalation study of 
BGB324 in healthy volunteers were presented at the 
2014 AACR Annual Meeting, where it was shown that 
adverse effects were only grade 1 and were reversible, 
gastrointestinal events being the most common [110].  
LIST OF ABBREVIATIONS  
Akt = V-akt murine thymoma viral oncogene 
homolog 
AML = acute myeloid leukemia. 
C1-TEN1 = TENsin homologue 
CNS = central nervous system 
EGFR = epidermal growth factor receptor 
EMT = epithelial to mesenchymal transition 
ERK = Extracellular signal-regulated kinases 
EZH2 = enhancer of zeste homolog 2 
GBM = glioblastoma multiforme 
GIST = gastrointestinal stromal tumors 
MAPK = mitogen-activated protein kinase 
MEK = Mitogen-activated protein kinase kinase 
mTOR = Mammalian target of rapamycin 
MZF1 = Myeloid Zinc Finger-1 
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NK = Natural Killer 
NSCLC = Non Small Cell Lung Cancer 
PI3K = Phosphoinositide-3-kinase 
ROS = reactive oxygen species 
RTK = receptor tyrosine kinases 
sAXL = soluble Axl 
SMC = smooth muscle cells 
TAM = Tyro3, Axl, Mer 
TAZ = transcriptional co-activator with PDZ-
binding motif 
TK = tyrosine kinase 
YAP1 = Yes-associated protein 1 
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